The Second School of Clinical Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China.
The Second Affiliated Hospital, Guangzhou University of Chinese Medicine (Guangdong Province Hospital of Traditional Chinese Medicine), Guangzhou, 510120, China; The Research Team on Bone and Joint Degeneration and Injury, Guangdong Provincial Academy of Traditional Chinese Medicine, Guangzhou, 510120, China.
Complement Ther Clin Pract. 2021 Aug;44:101419. doi: 10.1016/j.ctcp.2021.101419. Epub 2021 May 24.
Chinese patent medicines (CPMs) have gained increasing attention for the treatment of primary osteoporosis (POP), but there is a lack of high-quality evidence regarding their efficacy. We conducted a network meta-analysis that considered both direct and indirect comparisons to assess and rank the efficacy and safety of CPMs for POP.
Seven electronic databases were searched from their inception to May 2020. A random effects model was applied within a frequentist framework.
Thirty-eight studies with 16 kinds of medicines (13 CPMs, 3 Western medicines) and 3,941 patients were included in this study. This study showed that Jintiange capsule was the most efficacious for increasing the L2-L4 average bone mineral density (BMD) and that Zuogui Wan was the most efficacious for increasing the femoral neck BMD. Compared with calcium, Gusongjiangu Wan (RR = 10.04, 95% CI 1.36-74.32, p = 0.008), Gushukang granules (RR = 12.63, 95% CI 2.02-78.99, p = 0.015) and Xianling Gubao capsule (RR = 6.06, 95% CI 1.38-26.65, p = 0.0003) had fewer adverse reactions.
In the treatment of POP, Jintiange capsule and Zuogui Wan are effective CPMs for improving the BMD of the lumbar spine and femoral neck, respectively.
中药（CPM）在治疗原发性骨质疏松症（POP）方面受到越来越多的关注，但关于其疗效的高质量证据仍然缺乏。我们进行了一项网络荟萃分析，同时考虑了直接和间接比较，以评估和排名 CPM 治疗 POP 的疗效和安全性。
从成立到 2020 年 5 月，我们在七个电子数据库中进行了搜索。在一个频率论框架内应用了随机效应模型。
本研究共纳入 38 项研究，涉及 16 种药物（13 种 CPM，3 种西药）和 3941 名患者。本研究表明，金天格胶囊对增加 L2-L4 平均骨密度（BMD）最有效，而左归丸对增加股骨颈 BMD 最有效。与钙相比，骨松关节丸（RR=10.04，95%CI 1.36-74.32，p=0.008）、骨疏康颗粒（RR=12.63，95%CI 2.02-78.99，p=0.015）和仙灵骨葆胶囊（RR=6.06，95%CI 1.38-26.65，p=0.0003）的不良反应较少。
在治疗 POP 方面，金天格胶囊和左归丸是分别改善腰椎和股骨颈 BMD 的有效 CPM。
